Alzheimer's drug trials to take different approach
By USA Today
Published: Sunday, Oct. 7, 2012, 5:40 p.m.
Timing might be everything when it comes to treating Alzheimer's disease, according to research being presented on Monday at a meeting of the American Neurological Association in Boston.
There is no cure for the disease, which affects more than 5 million people in the country, and numbers are expected to triple by 2050.
Researchers will discuss findings on two large drug trials. Results announced last summer found that they failed to improve cognition or daily functioning compared with a placebo. The bapineuzumab and solanezumab therapies were done on patients with mild to moderate dementia. The drugs target beta amyloid, a protein in the brain believed to cause the disease.
“We think we've been starting trials too late in the progression of the disease,” said Laurie Ryan of the National Institute on Aging.
Scientists are discovering mechanisms of the disease and how it progresses. A large study in the New England Journal of Medicine found that brain changes begin as early as 25 years before the onset of symptoms.
“I'm worried that we're intervening too late and with too little” of the drugs, said Reisa Sperling of Brigham and Women's Hospital in Boston.
Show commenting policy
TribLive commenting policy
- Hearing to determine fate of sergeant accused of killing 2 deaf Iraqi boys
- Precautions lack year since fatal blast at plant
- IRS awards millions in bonuses to its people who don’t pay taxes
- Foundation gives $13M to promote Obamacare
- Details about USS Cole suspect’s stint in CIA custody must be turned over
- 69% back birth control mandate
- Gun background checks miss fugitives
- Little toxicity data exists for tainted W.Va. water
- Medicaid paid $12M for Illinois dead, audit finds
- Hopes high for muscular dystrophy drug
- Justices critical of Ohio law punishing campaign lies